Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease
An erratum to this article was published (Nat Med, Aug 2024 ↗)
Study context
- Population
- Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD); randomised trials 2016–2022
- Participants
- 27,317 participants26 trials
- Comparison
- Fixed-dose combination (FDC) therapy vs control
- Outcome
- All-cause mortality, fatal and nonfatal ASCVD events, adverse events, SBP, LDL-C and adherence
Methodological detailsfixed-effect meta-analysis
- Fixed-effect meta-analysis
Pooled result
As reported in the abstract
FDCRelative risk (95% CI)
All-cause mortality: 5.6%vs 6.3%; I2 = 0%; 4 trials, 16,278 participants
0.89(0.78–1.00)
Fatal and nonfatal ASCVD events: 6.1%vs 8.4%; I2 = 0%; 5 trials, 15,503 participants
0.71(0.63–0.79)
Further pooled results
MACE, exclusively secondary prevention population (1 trial)
- FDC reduced risk of MACE
- 24%
Safety
- Higher rates of adverse events with FDC in primary and mixed secondary prevention populations
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →